Alembic Pharmaceuticals surged 12% to Rs 1,089.80 after securing USFDA approval for its generic Doxorubicin Hydrochloride Liposome Injection, used in treating cancers like ovarian cancer and multiple myeloma. The U.S. market size for the drug is estimated at $29 million. Alembic now holds 224 USFDA approvals and remains technically strong, trading above key moving averages despite recent market volatility.